JAKARTA -- mClinica, a Singapore-headquartered health tech startup focused on the pharmaceutical industry, is planning to raise $20 million in its Series B round, just months after closing a bridge deal with U.S.-based Susquehanna International Group, a company executive told DealStreetAsia.
The bridge round was closed just before the coronavirus crisis struck the globe, crippling investments across sectors.
